Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
Screen a stock
TERMINAL
RD

RDYStockDr. Reddy`s Laboratories Ltd. - ADR

New York Stock Exchange · Healthcare · IN

$14.89 last close 2026-11-20
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment RDY's does — no target price to set, unlike a price alert.

Sharia status
NOT YET SCREENED
Not screened yet — no methodology has been established for this symbol
HTR non-permissible income <0.01%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure4 of 5 timeframes bullish · 82.6% aligned
VWAPPrice below VWAP ($14.89)
VolumeRelative volume 2.8× the 20-day average
Momentum10-day rate of change +0.8%
Market & analysts
Price target
$14.92
+0.2% · 5 analysts
Institutional own.
16.4%
of shares
Momentum (10d)
+0.8%
rate of change
SMC grade
D · 47
82.6% aligned
1.10% *
Purification ratio (secondary provider, uncertain)
<0.01%
Non-permissible income — HTR, from filings (2025-03-31)
D · 47
SMC grade — 82.6% timeframe alignment
+0.8%
Rate of change (10d)
$14.92
Price target (+0.2%) · 5 analysts
16.4%
Institutional ownership

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for RDY — this runs off the critical path so the page paints first. It will appear here on its own.

Shariah-compliant alternatives

Compliant companies in Drug Manufacturers - Specialty & Generic listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
GALDYGalderma Group AG - ADR $47.7B —
HLNHaleon plc - ADR $44.4B —
NBIXNeurocrine Biosciences, Inc. $15.9B —
ALKSAlkermes plc $7.9B —
HIMSHims & Hers Health Inc - Ordinary Shares - Class A $7.3B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold RDY

1 of the 227 funds whose filed holdings we currently hold own RDY shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns RDY.

Shariah funds
FundRDY in fundFund compliant by weight
SPWO SP Funds S&P World (ex-US) ETF 0.08% 87%

Sorted by RDY’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names RDY once, so a bond is not counted as the shares; 1 more fund name RDY in a way we cannot separate from its bonds, and is not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding RDY
InvestorFirmPositionWeightAs of
Peter Brown Renaissance Technologies $88M 0.1% 2026-09-30
Israel Englander Millennium Management $35M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $14M 0.0% 2026-09-30
Jeremy Grantham GMO $8M 0.0% 2026-09-30
David Shaw D. E. Shaw & Co. $4M 0.0% 2026-09-30
Steven Cohen Point72 Asset Management $1M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

15.2714.2813.2912.2911.302025-11-242026-05-272026-11-20

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
14.50
S2
14.65
S1
14.74
PIVOT
14.89
R1
14.98
R2
15.13
R3
15.22

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
11.58 – 12.92
±5.48% from 12.25, made 2026-09-28 · resolves 2026-10-05
STRONG BUY
from 19 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG BUY
19 indicators
OscillatorsSTRONG SELL
0 buy · 4 neutral · 3 sell
Moving averagesSTRONG BUY
12 buy · 0 neutral · 0 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)68.10NEUTRAL
Stochastic %K (14)75.86NEUTRAL
CCI (20)77.81NEUTRAL
Williams %R (14)-24.14NEUTRAL
MACD (12,26,9)-0.04SELL
ROC (10)-0.13SELL
Momentum (10)-0.02SELL
EMA (10)14.76BUY
SMA (10)14.84BUY
EMA (20)14.45BUY
SMA (20)14.55BUY
EMA (30)14.14BUY
SMA (30)14.04BUY
EMA (50)13.70BUY
SMA (50)13.34BUY
EMA (100)13.31BUY
SMA (100)12.85BUY
EMA (200)13.39BUY
SMA (200)13.25BUY

About Dr. Reddy`s Laboratories Ltd. - ADR

Healthcare · Drug Manufacturers - Specialty & Generic

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

drreddys.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BULLISH 64
⏰ 4H BULLISH 39
🕐 1H RANGING 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

+0.8%
Rate of change (10d)
2.8×
Volume vs its 20-day average
0.47
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-17 · Asset managers net 895049 (-19081)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.